High efficiency retroviral vector which contains genetically engineered cellular non-coding sequence harboring splicing acceptor
Abstract:
The present invention provides a safe and highly efficient retroviral vector derived from the MLV (murine leukemia virus) for use in gene therapy, which lacks viral coding sequences but contains the genetically engineered EF Iα non-coding sequence harboring splicing acceptor.
Information query
Patent Agency Ranking
0/0